Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented DehydraTECH(TM) Technology Increases Bioavailability in Lipophilic Drugs for Potential Hypertension, Epilepsy Treatments

  • The bioavailability enhancement technologies and services market is expected to reach $10 billion by 2035, growing at a CAGR of approximately 11%
  • Drug developers are shifting focus to the development of lipophilic drug compounds, which increases bioavailability
  • DehydraTECH-enabled drugs improve the speed of onset, increase bioavailability, increases brain absorption, and reduces drug administration costs
  • Lexaria’s DehydraTECH has 34 patents granted worldwide and many more pending across several categories of fat-soluble active molecules and drugs
  • The company operates through four separate subsidiaries to explore the potential and options for the use of DehydraTECH in respective industries

Bioavailability is the ability of a drug or other substance to be absorbed and used by the body – and in recent years, it has become an integral part of drug pharmacokinetics. The bioavailability enhancement technologies and services market is expected to reach $10 billion by 2035, growing at a CAGR of approximately 11%. Drug developers have shifted focus to developing lipophilic drug compounds, undertaking new efforts to identify enhancement techniques that mitigate the challenge of low bioavailability and stability (

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has developed its patented DehydraTECH(TM) technology to improve how active pharmaceutical ingredients (“APIs”) enter the bloodstream, promoting healthier oral digestion, increasing the effectiveness of lipophilic molecules, and increasing the bioavailability of targeted substances. DehydraTECH promotes fast-acting, less expensive, and more effective oral drug delivery, and it has been thoroughly evaluated through in vivo, in vitro, and human clinical testing.

DehydraTECH is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, and over-the-counter capsules, pills, tablets, oral suspensions and more. The benefits of DehydraTECH include the following:

  • Improves the speed of onset, with effects felt in minutes
  • Increases bioavailability by more effectively delivering the drug into the bloodstream
  • Increases brain absorption, with testing suggesting up to 10x improvement
  • Reduces drug administration costs with a higher ratio of drug delivery

To date, Lexaria has been granted 34 patents, with several more pending worldwide, including DehydraTECH-CBD for the potential treatment of hypertension, epilepsy, and more. Lexaria is also exploring food and beverage compositions infused with lipophilic active agents – improving bioavailability through food and drink. Through animal studies, DehydraTECH has shown the ability to elevate the quantity of the drug delivered across the blood-brain barrier by as much as 1,700 percent, which has initiated additional new patent applications and has opened possibilities for improved drug delivery.

Lexaria operates four subsidiary companies to focus on different commercial opportunities in their respective industries: Lexaria Pharma Corp. investigating new products for hypertension, anti-viral treatments, and other drug classes; Lexaria Nicotine Corp. (16.67% owned by Altria Ventures Inc.), investigating oral non-combusted tobacco-derived nicotine formats; Lexaria Hemp Corp. pursuing business-to-business opportunities with cannabinoids such as cannabidiol from hemp; and Lexaria Canpharm Corp. operating a state-of-the-art Health Canada licensed laboratory capable of developing novel psychotropic cannabinoid formulations for potential commercialization in sectors where it is federally legal to do so.

Lexaria’s DehydraTECH is a revolutionary technology that makes it possible to deliver bioactive substances topically or by oral ingestion without the need for unhealthy practices of inhalational dosing where applicable and without the need for co-administration with unhealthy sugars or sweeteners commonly used to mask bitter tastes. It provides power acceleration of intestinal absorption and requires fewer quantities of drugs to achieve desired results.

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit

MissionIR (MIR)
Atlanta, Georgia
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all

This entry was posted in Lexaria Bioscience Corp. LEXX. Bookmark the permalink.

Comments are closed.